NCT07476378 2026-03-17
Archonc-001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
Clinical Trials
46 trialsNCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT07412405 2026-02-17
ACITAC-001
Instituto Distrital de Ciencia, BiotecnologÃa e Innovación en Salud - IDCBIS
Phase NA Not yet recruiting
NCT07383233 2026-02-03
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma
Tianjin First Central Hospital
Phase 1 Not yet recruiting
NCT07352267 2026-01-20
Diagnostic Value and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy Versus Transbronchial Needle Aspiration in the Diagnosis of Lymphoma: a Randomized Controlled Trial
China-Japan Friendship Hospital
Phase NA Not yet recruiting
NCT05544968 2026-01-12
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07335094 2026-01-12
A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy
Zhujiang Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07289087 2025-12-17
QOL-ONE PRO-CT
Associazione Qol-one
Not yet recruiting
NCT07285174 2025-12-16
Shanghai Lymphoma Clinical Cohort
Ruijin Hospital
Not yet recruiting
NCT07286539 2025-12-16
PEPOH
University of Salamanca
Phase NA Not yet recruiting
NCT07259941 2025-12-02
PET-CT in Lymphoma Among the Eldery
Assiut University
Not yet recruiting
NCT07244380 2025-11-24
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
Hebei Senlang Biotechnology Inc., Ltd.
Phase 2 Not yet recruiting
NCT07206264 2025-10-03
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07198958 2025-09-30
MITOX
IRCCS San Raffaele
Not yet recruiting
NCT07196111 2025-09-29
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT07192471 2025-09-25
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07131449 2025-08-20
succinylation
The First Affiliated Hospital of Xinxiang Medical College
Not yet recruiting
NCT07048353 2025-07-02
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT07020260 2025-06-13
PACMAN
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT05969821 2025-06-12
CHIS
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
NCT07013435 2025-06-10
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Massachusetts General Hospital
Phase NA Not yet recruiting
NCT07014293 2025-06-10
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Massachusetts General Hospital
Phase NA Not yet recruiting
NCT07008872 2025-06-06
CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia
Tianjin First Central Hospital
Phase NA Not yet recruiting
NCT06788600 2025-04-02
WGc-043
Ruijin Hospital
Not yet recruiting
NCT06757478 2025-03-18
A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma
First Affiliated Hospital of Ningbo University
Not yet recruiting
NCT06867536 2025-03-18
GLOHRT-01
Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06817759 2025-02-10
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Ciusss de L'Est de l'Île de Montréal
Phase NA Not yet recruiting
NCT06471296 2025-01-15
VIRONMENT
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
NCT06557330 2025-01-06
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Fox Chase Cancer Center
Phase 2 Not yet recruiting
NCT06737835 2024-12-17
Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma
Assiut University
Not yet recruiting
NCT06647329 2024-10-17
CAR-T Therapy
Zhengzhou University
Phase 1 Not yet recruiting
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06573099 2024-08-27
A Real-World Study on Extranodal Lymphoma
Ruijin Hospital
Not yet recruiting
NCT06573151 2024-08-27
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06573645 2024-08-27
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT05545202 2024-04-03
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pharmacosmos A/S
Phase 4 Not yet recruiting
NCT06262789 2024-02-16
RAT-HEMATO
University Hospital, Angers
Phase NA Not yet recruiting
NCT05979857 2023-11-22
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
Salarius Pharmaceuticals, LLC
Phase EARLY_PHASE1 Not yet recruiting
NCT06070246 2023-10-06
Navigating the Clinical Research Process for Lymphoma
Power Life Sciences Inc.
Not yet recruiting
NCT05788107 2023-08-09
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT05775705 2023-03-20
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
Phase 3 Not yet recruiting
NCT05616325 2022-11-15
FERTILymph
University Hospital, Lille
Not yet recruiting
NCT05391490 2022-05-26
KCAT19
University College, London
Phase 1 Not yet recruiting
NCT05055791 2021-09-24
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Not yet recruiting